NCT07938099
Real-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria changed
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Major adverse cardiovascular events (MACE)
Timeframe: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.
All-cause mortality
Timeframe: Patients were followed up from the index date until death, loss to follow-up, or August 31, 2026, whichever occurred first.
Arms and interventions
PCSK9 monoclonal antibody plus statins
PCSK9 monoclonal antibodies include evolocumab, alirocumab, t
Cholesterol absorption inhibitors combined with statins
Cholesterol absorption inhibitors included ezetimibe and hyzetimibe, and statins included lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and pitavastatin. Exposure was identified through medical insurance reimbursement claims.
Sites
1 site in 1 country
- Nanjing medical universityNanjing, Jiangsu, China